File articles

Coronavirus y corazón ¿Cómo deben prepararse los cardiólogos?

Convalescent Plasma for Severe Pneumonia from COVID-19

Convalescent Plasma for Severe Pneumonia from COVID-19

After testing multiple drugs and drug combinations in COVID-19 patients, only Remdesivir – for hospitalized patients – and dexamethasone – in patients requiring Oxygen – have shown some benefits.  Convalescent plasma has been used for years assuming passive immunization might help control the infection until a specific immune response is established in the infected person.

El acceso radial se asocia a menor mortalidad y menor sangrado en los pacientes cursando un infarto con supradesnivel del segmento ST que reciben angioplastia primaria.

The Transradial Approach Continues to Be the Best for Primary PCI

The transradial approach has been associated to lower mortality and bleeding rates in patients receiving primary PCI for ST elevation MI.  This had been called into question by the recent SAFARI-STEMI, but after including its outcomes in a new meta-analysis, the scales tilted slightly in favor of the transradial approach vs. the transfemoral.  The transradial

¿Cirugía bariátrica por cateterismo?

Transcatheter Bariatric Surgery?

This pilot study has shown transcatheter embolotherapy targeted to the left gastric artery is well tolerated and promotes significant weight reduction compared against a sham procedure. Obesity has been linked to higher rates of cardiovascular and metabolic events. Diets and medical strategies are often ineffective and hardly sustainable over time.  Bariatric procedures, though effective, are

autoexpandible

Balloon-Expandable Valve Outdoes Itself

The objective of this paper recently published in J Am Coll Cardiol Intv was to compare the outcomes of transcatheter aortic valve replacement (TAVR) with the new Sapien 3 Ultra vs. Sapien 3. Successful implantation was extremely high with both balloon-expandable devices, which also had a very low adverse event rates. However, Sapien Ultra was significantly better

Dietas bajas en carbohidratos y progresión de la calcificación coronaria

Low-Carb Diet and Coronary Artery Calcium Progression

People on low carb diets since a young age present increased risk of coronary artery calcium progression, particularly when carbs are replaced by animal protein and fat.  This study included CARDIA participants (Coronary Artery Risk Development in Young Adults) receiving a CT scan between the years 2000 and 2001 for calcium scoring, who also completed

AHA 2020 | Anticoagulación post TAVI en pacientes con fibrilación auricular

AHA 2020 | Post-TAVR Anticoagulation in Patients with Atrial Fibrillation

Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation discharged after successful transcatheter aortic valve replacement (TAVR) compared with classic vitamin K inhibitors. Optimal anticoagulation in patients with atrial fibrillation (AF) undergoing TAVR is unclear. We are actually just starting to know what the ideal antiplatelet therapy is for patients undergoing

AHA 2020 | AFFIRM-AHF: Suplemento de hierro y menos hospitalizaciones por insuficiencia cardíaca

AHA 2020 | Effect of Evolocumab in Complex Coronary Revascularization

Evolocumab, a PCSK9 inhibitor, has shown significant reduction of complex coronary disease requiring revascularization (be it PCI or CABG). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce plaque regression and could eventually reduce the risk of coronary revascularization, especially complex revascularization.  The FOURIER study randomized 27564 patients with stable CAD already on statins to evolocumab

AHA 2020 | Ácidos grasos omega 3 sin beneficio cardiovascular y con más fibrilación auricular

AHA 2020 | Omega-3 Fatty Acids Provide No Cardiovascular Benefits and Cause More Atrial Fibrillation

Results confirm the interim analysis, whereby the study was suspended for futility. Omega-3 fatty acids do not reduce cardiovascular events in patients with high triglycerides and low HDL. Previous studies, such as REDUCE-IT, had shown positive results, but given this new research (presented at the American Heart Association [AHA] 2020 Congress and simultaneously published in

AHA 2020 | EMPATROPISM: Empagliflozina en no diabéticos con insuficiencia cardíaca

AHA 2020 | EMPATROPISM: Empagliflozin in Non-Diabetics with Cardiac Failure

Empagliflozin improves cardiac function, exercise capacity and quality of life in non-diabetic patients with cardiac failure and deteriorated ejection fraction.  These findings were presented during the scientific sessions at AHA 2020 and published simultaneously in JACC. EMPATROPISM outcomes are on the same line as other studies using sodium glucose 2 cotransporter inhibitors (SGLT2) which showed

Top